Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.88 USD | -4.20% | -4.93% | -18.40% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.40% | 2.4B | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.21% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Wedbush Lowers Price Target for Intellia Therapeutics to $55 From $108, Maintains Neutral Rating